Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 11/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985599 | 0.93 | PDK4 (0.42) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL19413525 | 0.89 | PDK4 (0.39) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL3434214 | 0.89 | STS (0.39) | PDK4HTR6GPR119ESR2NR1H2 | |
| SCHEMBL15598574 | 0.88 | PDK4 (0.36) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL4281295 | 0.87 | PDK4 (0.42) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL23123262 | 0.87 | PKM (0.36) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL612208 | 0.87 | PDK4 (0.37) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL4083087 | 0.85 | PDK4 (0.48) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL2458379 | 0.84 | QDPR (0.38) | ESR2ADORA1 | |
| SCHEMBL308840 | 0.84 | BACE1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| EP-4691465-A2 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | The Trustees of Columbia University in the City of New York (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4036094-B1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | UNIV COLUMBIA (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-0920421-A1 | ISOXAZOLINE DERIVATIVES USEFUL AS ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0912561-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 1999-05-06 | — | — | EP | disclosed |
| US-5885999-A | TREATMENT OR PREVENTION OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA | MERCK SHARP & DOHME LTD. (GB) | 1999-03-23 | — | — | US | disclosed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| EP-0880512-A1 | NOVEL AROMATIC PIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998007708-A1 | ISOXAZOLINE DERIVATIVES USEFUL AS ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997043280-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997028141-A1 | NOVEL AROMATIC PIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | PDK4 922/4885HTR6 1768/4885GRM5 2939/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | PDK4 4519/4885HTR6 1995/4885GRM5 2922/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | PDK4 3716/4885HTR6 2814/4885GRM5 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.